Liposomal distribution in malignant glioma: Possibilities for therapy

Nuclear Medicine Communications

Volumn 18, Issue 1, 1997, Pages 17-23

  Khalifa, A ^a   Dodds, D ^a   Rampling, R ^a   Murray, T ^b   Paterson, J ^c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; LIPOSOME; LIPOSOME IN 111;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; RADIOISOTOPE THERAPY; WHOLE BODY SCINTISCANNING;

EID: 0031038532     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199701000-00005     Document Type: Article

References (15)

1. Nelson DF, Nelson JS, Davis DR et al Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurol Oncol 1985; 3: 99-103.
2. Komblith PL, Walker MD. Chemotherapy for malignant gliomas. J Neurosurg 1988; 68: 1-17
3. Neuwelt EA, Howieson J, Frenkel EP et al Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification. Neurosurgery 1986; 19: 573-582.
4. Hockberg FH, Pruitt AA, Beck DO et al The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 1985; 63: 876-880.
5. Gabizon A, Isacson R, Libson E et al Clinical studies of liposome encapsulated doxorubicin. Acta Oncologica 1994; 33: 779-786.
6. Gregoriadis G. Liposomes as drug carriers. New York: John Wiley, 1988.
7. Gabizon A, Chisin R, Amselem S et al Pharmacokinetic and imaging studies in patients receiving a formulation of liposome associated adriamycin. Br J Cancer 1991; 64: 1125-1132.
8. Guaglianone P, Chan K, DelaFlor-Weiss E et al Phase 1 clinical trial of liposomal daunorubicin in advanced malignancies. Proceedings of the Annual Meeting of the Society for Clinical Oncology 1992; 11: A361.
9. Proffitt RT, Williams L, Presant C et al Tumour imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice. J Nucl Med 1983; 24: 45-51.
10. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localisation of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res 1992; 52: 3255-3261.
11. Presant CA, Blayney D, Proffitt RT et al Preliminary report: Imaging of Kaposi sarcoma and lymphoma in AIDS with In-111 labelled liposomes. Lancet 1990; 335: 1307-1309.
12. Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: A clinical perspective. Crit Rev Oncol Haematol 1992; 12: 231-242.
13. Gabizon A, Aselem A, Goren S et al Preclinical and clinical experience with a doxorubicin-liposome preparation. J Liposome Res 1990; 1: 491-502.
14. Owen RR, Sells RA, Gilmore IT, New RR, Stringer REA. Phase 1 clinical evaluation of liposome entrapped doxorubicin (Lip-dox) in patients with primary and metastatic hepatic malignancy. Anticancer Drugs 1992; 3: 101-107.
15. Uziely B, Jeffers S, Isacson R et al Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase 1 studies. J Clin Oncol 1995; 13: 1777-1785.